LU88122A1 - Anticorps purifies specifiquement developpes contre le cdw52 - Google Patents

Anticorps purifies specifiquement developpes contre le cdw52 Download PDF

Info

Publication number
LU88122A1
LU88122A1 LU88122A LU88122A LU88122A1 LU 88122 A1 LU88122 A1 LU 88122A1 LU 88122 A LU88122 A LU 88122A LU 88122 A LU88122 A LU 88122A LU 88122 A1 LU88122 A1 LU 88122A1
Authority
LU
Luxembourg
Prior art keywords
antibody
column
cdw52
prepn
purified
Prior art date
Application number
LU88122A
Other languages
English (en)
French (fr)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LU88122A1 publication Critical patent/LU88122A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU88122A 1990-10-17 1992-05-27 Anticorps purifies specifiquement developpes contre le cdw52 LU88122A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Publications (1)

Publication Number Publication Date
LU88122A1 true LU88122A1 (fr) 1993-03-15

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88122A LU88122A1 (fr) 1990-10-17 1992-05-27 Anticorps purifies specifiquement developpes contre le cdw52

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATA900791A (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681455A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2081742B1 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL102726A (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY119030A (enExample)
NZ (2) NZ240247A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA918259B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2120911A1 (en) * 1991-10-15 1993-04-29 Geoffrey Hale Medicaments
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
KR19990036028A (ko) † 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
KR100317188B1 (ko) 1996-02-09 2002-02-19 스타르크, 카르크 사람TNFα와결합하는사람항체
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
DK1404428T3 (da) * 2001-06-05 2006-10-30 Genetics Inst Llc Fremgangsmåder til oprensning af stærkt anioniske proteiner
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
DK2261230T3 (en) 2002-09-11 2017-06-12 Chugai Pharmaceutical Co Ltd Method of Protein Purification.
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
CN1956731A (zh) * 2003-12-22 2007-05-02 根茨美公司 抗－cd52抗体对糖尿病的治疗
EP1869065B1 (en) 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20170113704A (ko) 2009-05-13 2017-10-12 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MY181081A (en) 2013-12-27 2020-12-17 Chugai Pharmaceutical Co Ltd Method for purifying antibody having low isoelectric point
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US10858391B2 (en) 2015-07-31 2020-12-08 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
JP7273142B2 (ja) 2019-03-29 2023-05-12 旭化成メディカル株式会社 タンパク質の精製方法
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
WO2020209318A1 (ja) 2019-04-10 2020-10-15 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
EP4353735A4 (en) 2021-06-10 2024-10-16 Mitsubishi Chemical Corporation SYNTHETIC ADSORBENT, ANTIBODY PURIFYING METHOD, AND ANTIBODY PRODUCTION METHOD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
GB2216126B (en) * 1988-02-12 1992-06-03 Medical Res Council Antibodies to the antigen campath-1

Also Published As

Publication number Publication date
CH681455A5 (enExample) 1993-03-31
GB2253397A (en) 1992-09-09
FI922380L (fi) 1992-05-25
CH681305A5 (enExample) 1993-02-26
US5644036A (en) 1997-07-01
KR960015399B1 (ko) 1996-11-13
BR1100358A (pt) 2000-03-28
MY119030A (en) 2005-03-31
AU658926B2 (en) 1995-05-04
PT100988B (pt) 1999-08-31
PT99248B (pt) 1999-04-30
IT1250064B (it) 1995-03-30
EP0504363B1 (en) 1998-01-21
TW283710B (enExample) 1996-08-21
IL102726A0 (en) 1993-01-31
DK0504363T3 (da) 1998-09-21
GB9022547D0 (en) 1990-11-28
GR3026588T3 (en) 1998-07-31
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
BE1004226A5 (fr) 1992-10-13
WO1992007084A1 (en) 1992-04-30
NZ240247A (en) 1994-03-25
ES2112865T5 (es) 2007-09-16
EP0504363A1 (en) 1992-09-23
IL102726A (en) 2002-08-14
HUT64601A (en) 1994-01-28
ITRM910788A0 (it) 1991-10-16
JPH05504579A (ja) 1993-07-15
FI922380A0 (fi) 1992-05-25
DE69128774T2 (de) 1998-06-04
AU649078B2 (en) 1994-05-12
HU9202000D0 (en) 1992-10-28
EP0504363B2 (en) 2007-02-07
MY136210A (en) 2008-08-29
ES2081742B1 (es) 1996-10-01
GB9209529D0 (en) 1992-07-01
IE913560A1 (en) 1992-04-22
FI110002B (fi) 2002-11-15
FR2668164A1 (fr) 1992-04-24
ES2112865T3 (es) 1998-04-16
KR920703108A (ko) 1992-12-17
GR910100425A (el) 1992-09-25
ZA918259B (en) 1993-04-16
FI922824L (fi) 1992-06-17
DK0504363T4 (da) 2007-05-29
AU716402B2 (en) 2000-02-24
KR100193314B1 (ko) 1999-06-15
NZ244114A (en) 1995-06-27
ES2081742A1 (es) 1996-03-01
GR920100471A (el) 1994-06-30
PT100988A (pt) 1994-02-28
CA2069481C (en) 2003-07-29
ATE162552T1 (de) 1998-02-15
IL99761A0 (en) 1992-08-18
PT99248A (pt) 1993-06-30
FI922824A0 (fi) 1992-06-17
FR2668164B1 (enExample) 1995-04-14
FR2677997A1 (fr) 1992-12-24
MX9203794A (es) 1992-07-01
AU7024294A (en) 1995-01-05
FI110003B (fi) 2002-11-15
ITRM910788A1 (it) 1993-04-16
ZA926191B (en) 1993-04-16
ATA900791A (de) 1996-06-15
JP2638680B2 (ja) 1997-08-06
DE69128774D1 (de) 1998-02-26
AU2532192A (en) 1993-02-11
AU4521897A (en) 1998-02-12
CA2069481A1 (en) 1992-04-18

Similar Documents

Publication Publication Date Title
LU88122A1 (fr) Anticorps purifies specifiquement developpes contre le cdw52
ES8100502A1 (es) Un procedimiento para purificar proteinas con pesos moleculares superiores a 12.000,en particular interferon
EP0185034A4 (enExample)
CA1208130A (en) ULTRAPURIFICATION OF FACTOR VIII
EP0239565A3 (en) Method of and apparatus for separating proteins
FR2487642B2 (fr) Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions
EP0310719A1 (en) Method for purification of antibodies
Coligan et al. Physical, chemical and immunological characterization of saline-extracted, concanavalin A-purified carcinoembryonic antigen
Ninfali et al. Goat immunoglobulin purification on phosphocellulose and DEAE Affi-Gel blue
ATE118782T1 (de) Reinigungsverfahren für interferon.
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY
FR2411202A1 (fr) Procede d'extraction et de purification de la globuline transporteur d'hormones thyroidiennes tbg
Haller et al. Isolation of human alpha-1 fetoprotein (AFP) from induced abortion material